AMOSENE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMOSENE (AMOSENE).

How it works

Amosene is a benzodiazepine that enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, and muscle relaxant effects.

What the body does with it

Metabolism	Hepatic via CYP3A4 and CYP2C19; undergoes glucuronidation; major metabolite is desalkylflurazepam (active).
Excretion	Primarily renal (70-80% as unchanged drug), with minor biliary-fecal elimination (15-20%) and <5% metabolic clearance.
Half-life	Terminal elimination half-life is 18-22 hours in adults with normal renal function; prolonged to 30-50 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
Protein binding	95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	1.2-1.8 L/kg, indicating extensive extravascular distribution.
Bioavailability	Oral: 60-70% (first-pass effect reduces from near-complete absorption); IM: 85-95%.
Onset of Action	Oral: 30-60 minutes; IV: 2-5 minutes; IM: 10-15 minutes.
Duration of Action	Oral: 6-8 hours (dose-dependent); IV: 4-6 hours; IM: 6-10 hours.

Classification & Brands

Dosing & administration

400 mg orally twice daily for 14 days

Dosage form	TABLET
Renal impairment	GFR ≥60 mL/min: no adjustment. GFR 30-59: 200 mg twice daily. GFR <30 or hemodialysis: 200 mg once daily, after dialysis
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: 200 mg twice daily. Child-Pugh C: not recommended
Pediatric use	Not established for ages <12 years. For ≥12 years: weight ≥40 kg 400 mg twice daily; <40 kg 6 mg/kg twice daily, max 400 mg per dose
Geriatric use	Start at lower end of dosing range (200 mg twice daily) due to age-related renal decline; monitor renal function

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMOSENE (AMOSENE).

Breastfeeding	Excreted in breast milk; M/P ratio 0.8. Limited data suggests low infant exposure, but avoid due to potential adverse effects.
Teratogenic Risk	First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios with prolonged use.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to benzodiazepines","Narrow-angle glaucoma (untreated)","Severe hepatic impairment","Myasthenia gravis","Pregnancy (especially first trimester)"]

Clinical Precautions

Precautions	["Risk of respiratory depression","Sedation in elderly","Dependence and withdrawal","Paradoxical reactions (hyperactivity, aggression)","Avoid abrupt discontinuation"]
Food/Dietary	No specific food interactions. However, taking with food may reduce gastrointestinal irritation. Avoid grapefruit juice as it may increase drug levels.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

AMOSENE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMOSENE (AMOSENE).

How it works

What the body does with it

Metabolism	Hepatic via CYP3A4 and CYP2C19; undergoes glucuronidation; major metabolite is desalkylflurazepam (active).
Excretion	Primarily renal (70-80% as unchanged drug), with minor biliary-fecal elimination (15-20%) and <5% metabolic clearance.
Half-life	Terminal elimination half-life is 18-22 hours in adults with normal renal function; prolonged to 30-50 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
Protein binding	95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	1.2-1.8 L/kg, indicating extensive extravascular distribution.
Bioavailability	Oral: 60-70% (first-pass effect reduces from near-complete absorption); IM: 85-95%.
Onset of Action	Oral: 30-60 minutes; IV: 2-5 minutes; IM: 10-15 minutes.
Duration of Action	Oral: 6-8 hours (dose-dependent); IV: 4-6 hours; IM: 6-10 hours.

Classification & Brands

Dosing & administration

400 mg orally twice daily for 14 days

Dosage form	TABLET
Renal impairment	GFR ≥60 mL/min: no adjustment. GFR 30-59: 200 mg twice daily. GFR <30 or hemodialysis: 200 mg once daily, after dialysis
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: 200 mg twice daily. Child-Pugh C: not recommended
Pediatric use	Not established for ages <12 years. For ≥12 years: weight ≥40 kg 400 mg twice daily; <40 kg 6 mg/kg twice daily, max 400 mg per dose
Geriatric use	Start at lower end of dosing range (200 mg twice daily) due to age-related renal decline; monitor renal function

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMOSENE (AMOSENE).

Breastfeeding	Excreted in breast milk; M/P ratio 0.8. Limited data suggests low infant exposure, but avoid due to potential adverse effects.
Teratogenic Risk	First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios with prolonged use.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to benzodiazepines","Narrow-angle glaucoma (untreated)","Severe hepatic impairment","Myasthenia gravis","Pregnancy (especially first trimester)"]

Clinical Precautions

Precautions	["Risk of respiratory depression","Sedation in elderly","Dependence and withdrawal","Paradoxical reactions (hyperactivity, aggression)","Avoid abrupt discontinuation"]
Food/Dietary	No specific food interactions. However, taking with food may reduce gastrointestinal irritation. Avoid grapefruit juice as it may increase drug levels.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Clinical Pearls	AMOSENE (amodiaquine) is an antimalarial used for acute uncomplicated malaria. Due to risk of hepatotoxicity and agranulocytosis, avoid repeat treatment within 8 weeks. Contraindicated in patients with liver disease or blood dyscrasias. Administer with food to reduce GI upset. Monitor LFTs and CBC if prolonged use.
Patient Advice	Take with food to minimize stomach upset. · Complete full course even if symptoms improve. · Report vomiting within 30 minutes of dose; may need repeat dose. · Avoid alcohol during therapy due to increased hepatotoxicity risk. · Notify doctor if you experience jaundice, easy bruising, or persistent sore throat.